This test requires a blood draw, so please ensure you can refer to a phlebotomist in the clients area before you order this test.

trublood® is a minimally invasive, diagnostic test that can clearly identify cancer in symptomatic patients. trublood® provides diagnostic information similar to that of a tissue biopsy when it is inconclusive or not possible. Based on the test result, therapy can be aligned.

trublood® was developed based on the results of several clinical studies and validated on more than 40,000 samples. These included samples from asymptomatic subjects undergoing screening tests such as mammograms, colonoscopies, PAP smears, serum CA markers and other clinical examinations, as well as more than 17,000 samples from patients with various cancers and patients with benign diseases.

Recommended for: 

• Symptomatic individuals who have been advised an invasive tissue biopsy to check for mailgnancy
• Patients where an invasive biopsy has been inconclusive or inconsistent with clinical observations
• Suspected metastatic relapse to rule out new primary.

Practical

Specimen

Whole blood 

Container

• 1 x 2 ml SST tube (yellow colour cap) 
• 2 x EDTA tubes (purple colour cap)

Volume

17 mL

Patient preparation

The patient must not have received any form of cancer therapy (radiation / chemo-therapy / surgery / endocrine therapy etc.) at least 15 days prior to collection of sample.
The patient must not have received oral or IV corticosteroids at least 15 days prior to collection of sample.
Patient has no current febrile or any other acute inflammatory illness.
Patient does not have acute exacerbation or flare-up of an inflammatory condition requiring escalation in medical therapy at least 5 days prior to collection of sample.
Patient has not received blood transfusion / PET-CT / CT scan at least 5 days prior to collection of sample.
Patient is not positive for HIV / HBV / HCV.